Industry unhappy at having to shoulder full EU PV fee burden
This article was originally published in SRA
European pharmaceutical industry bodies are unhappy that companies are being asked to share the whole burden of funding the EU's new pharmacovigilance activities. While they have generally welcomed the recent compromise deal on the new fees for these activities1,2, they are also disappointed that the fee level for safety referrals is significantly higher than originally proposed by the European Commission.
You may also be interested in...
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Mutual recognition of approvals and simplified rules on labeling could help to make COVID-19 vaccines more accessible to populations around the world.
The UK BioIndustry Association says the updated guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.